The Benlysta Market Overview 2025 report reveals that the market size has grown significantly over the past few years, with projections indicating further expansion.
The size of the Benlysta market has seen substantial growth in the past years. The market rose from $2,156.02 million in 2024 to $2,404.67 million in 2025, demonstrating a compound annual growth rate (CAGR) of 11.5%.
The Benlysta market is projected to reach $3,672.17 million in 2029, with a compound annual growth rate (CAGR) of 11.2%.
Download Your Free Sample of the 2025 Benlysta Market Report and Uncover Key Trends Now!Key growth drivers of the benlysta market include:
• Rising prevalence of Hepatitis B infections
• Inadequate vaccination coverage against hepatitis B
• Increased transmission among high-risk populations
• Interruptions in health services due to COVID-19 leading to reduced testing and prevention efforts.
The benlysta market covered in this report is segmented –
1) By Route Of Administration: Intravenous (IV), Subcutaneous (SC)
2) By Clinical Indication: Systemic Lupus Erythematosus (SLE), Lupus Nephritis (LN), Other Related Conditions
3) By End Users: Hospitals, Clinics, Home Care Settings, Specialty Pharmacies
Market trends in the benlysta market include:
• Advances in immunology are an emerging trend in the Benlysta global market.
• Innovative drug delivery systems are shaping the future of the market.
• Collaboration with research institutions is becoming increasingly common.
• The use of AI and machine learning in drug development heralds a significant trend.
The top competitors and leading players in the benlysta market are:
• Bayer Corporation
North America was the largest region in the benlysta market in 2024